InMed Pharmaceuticals (INM) 10% Owner LLC Buys $11K of Stock

ADAR1 Capital Management, LLC bought 8,021 shares of InMed Pharmaceuticals Inc. (INM) on October 14, 2026, for a total value of $10,667.93. This purchase adds to their significant stake, bringing their total holdings to over 91,000 shares.

Inside ADAR1 Capital Management's Trade

ADAR1 Capital Management, a beneficial owner of more than 10% of InMed Pharmaceuticals, executed this purchase at a price of $1.33 per share. This transaction follows a series of earlier buys, including purchases on October 5 and October 8, where they acquired 42,920 shares and 10,903 shares, respectively. The recent activity indicates a strong commitment to increasing their position in the pharmaceutical company.

Other Institutional Activity in InMed Pharmaceuticals

In addition to ADAR1 Capital Management, several other institutional investors have been active in InMed Pharmaceuticals. Vivo Capital, LLC increased its holdings by 399,188 shares, bringing its total to 798,377 shares valued at about $1,053,857. Squadron Capital Management LLC also grew its stake by 162,500 shares, ending with 325,000 shares worth approximately $429,000. These movements suggest that institutional interest in InMed remains robust.

InMed Pharmaceuticals Inc. Stock Down 0.8%

As of October 16, 2026, InMed Pharmaceuticals was recently trading around $1.32. This is below its 50-day moving average of $1.38 but above its 52-week low of $0.57. The stock is also approximately 43.3% below its 52-week high of $2.33, indicating that it may be in a consolidating phase.

Recent Earnings

InMed Pharmaceuticals has not reported any earnings data recently. However, its next earnings date is set for November 5, 2026, which could provide more insights into its financial performance moving forward.

Insider Buying and Selling at InMed Pharmaceuticals Inc.

ADAR1 Capital Management has been actively buying shares of InMed Pharmaceuticals. On September 16, 2026, they purchased 91,101 shares, valued at $118,076. This was followed by additional purchases of 42,920 shares on October 5, 2026, and 10,903 shares on October 8, 2026, both at $1.33 per share. The most recent purchase of 8,021 shares on October 14, 2026, further solidifies their position as a major stakeholder in the company.

Bottom Line

The continued buying by ADAR1 Capital Management suggests strong confidence in InMed Pharmaceuticals' future. Investors should watch for the upcoming earnings report on November 5, 2026, as it may offer crucial insights into the company's performance and strategy. The ongoing insider activity indicates that major stakeholders believe in the potential growth of InMed Pharmaceuticals in the competitive healthcare sector.